Breaking News Instant updates and real-time market news.

PFE

Pfizer

$39.53

-1.1 (-2.71%)

, VZ

Verizon

$55.09

-1.28 (-2.27%)

20:25
01/28/19
01/28
20:25
01/28/19
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include Pfizer (PFE), consensus 64c... Verizon (VZ), consensus $1.09... 3M Company (MMM), consensus $2.28... Lockheed Martin (LMT), consensus $4.40... Danaher (DHR), consensus $1.27... Biogen (BIIB), consensus $6.74... Allergan (AGN), consensus $4.16... HCA Healthcare (HCA), consensus $2.58... Corning (GLW), consensus 57c... PACCAR (PCAR), consensus $1.53... Rockwell Automation (ROK), consensus $1.99... Nucor (NUE), consensus $1.94... Harris (HRS), consensus $1.91... L3 Technologies (LLL), consensus $2.70... Dover (DOV), consensus $1.29... A. O. Smith (AOS), consensus 71c... PulteGroup (PHM), consensus $1.10... Harley-Davidson (HOG), consensus 28c... Polaris Industries (PII), consensus $1.82... Knight-Swift Transportation (KNX), consensus 85c... Graphic Packaging (GPK), consensus 19c... Commvault Systems (CVLT), consensus 42c... Brinker International (EAT), consensus 89c.

PFE

Pfizer

$39.53

-1.1 (-2.71%)

VZ

Verizon

$55.09

-1.28 (-2.27%)

MMM

3M

$193.20

-2.71 (-1.38%)

LMT

Lockheed Martin

$287.84

0.81 (0.28%)

DHR

Danaher

$106.01

-0.3 (-0.28%)

BIIB

Biogen

$329.68

-7.12 (-2.11%)

AGN

Allergan

$158.72

-1.92 (-1.20%)

HCA

HCA Healthcare

$131.62

-1.27 (-0.96%)

GLW

Corning

$30.37

0.02 (0.07%)

PCAR

Paccar

$61.30

-1.34 (-2.14%)

ROK

Rockwell Automation

$163.53

-2.78 (-1.67%)

NUE

Nucor

$58.45

0.33 (0.57%)

HRS

Harris

$142.88

-0.6 (-0.42%)

LLL

L3 Technologies

$183.86

-0.635 (-0.34%)

DOV

Dover

$79.19

-0.31 (-0.39%)

AOS

A.O. Smith

$48.18

0.6 (1.26%)

PHM

PulteGroup

$27.03

0.07 (0.26%)

HOG

Harley-Davidson

$36.61

-0.25 (-0.68%)

PII

Polaris Industries

$84.82

-2.235 (-2.57%)

KNX

Knight-Swift

$30.07

-0.71 (-2.31%)

GPK

Graphic Packaging

$12.17

0.02 (0.16%)

CVLT

Commvault

$61.60

-0.65 (-1.04%)

EAT

Brinker

$47.38

0.87 (1.87%)

  • 28

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 29

    Jan

  • 30

    Jan

  • 01

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 11

    Feb

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 03

    Mar

  • 18

    May

PFE Pfizer
$39.53

-1.1 (-2.71%)

01/28/19
UBSW
01/28/19
NO CHANGE
Target $109
UBSW
Buy
Exact Sciences price target raised to $109 from $100 at UBS
UBS analyst Daniel Brennan raised his price target on Exact Sciences (EXAS) to $109 from $100 following meetings with management. The analyst raised his doctor additions forecast as well as his Street-high revenue forecasts and still sees room for upside. He sees the additions upside coming as the result of a doubling of ad spending, the addition of Pfizer (PFE and its salesforce, and the doubling of its own salesforce. Brennan reiterated his Buy rating on Exact Sciences shares.
01/23/19
UBSW
01/23/19
DOWNGRADE
Target $46
UBSW
Neutral
Pfizer downgraded to Neutral from Buy at UBS
UBS analyst Navin Jacob downgraded Pfizer to Neutral and lowered his price target for the shares to $46 from $48.50 after assuming coverage of the name. The analyst cites valuation for the downgrade to Neutral.
01/25/19
COWN
01/25/19
NO CHANGE
Target $100
COWN
Outperform
Exact Sciences meeting affirms enthusiasm, says Cowen
Cowen analyst Doug Schenkel met with Exact Sciences (EXAS) management, which he said affirmed his enthusiasm about the company. The analyst said Pfizer (PFE) played a key role in driving Q4 physician adds. He sees little reason for regressed Street expectations and noted that the company is stepping up its pipeline efforts. Schenkel reiterated his Outperform rating and $100 price target and called Exact Sciences a top pick for 2019.
01/23/19
01/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Tesla (TSLA) downgraded to Underperform from Sector Perform at RBC Capital with analyst Joseph Spak saying the company's more "tactful messaging" conveys downward pressure to growth expectations and also sees the "realities" of Tesla becoming a volume player highlighting its "challenges to scale and deliver high volume at high ASPs/margins." 2. Lowe's (LOW) downgraded to Hold from Buy at Loop Capital with analyst Laura Champine saying she thinks she was previously too optimistic on Lowe's likely margin progression. 3. Williams-Sonoma (WSM) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Simeon Gutman saying he believes top and bottom-line pressures will intensify in 2019. 4. Merck (MRK) downgraded to Market Perform from Outperform at BMO Capital with analyst Alex Arfaei citing the company's over-dependence on Keytruda, the Street's high expectations, and his views on upcoming competitor trials combining for a more balanced risk-reward on Merck. 5. Pfizer (PFE) and Mylan (MYL) were downgraded to Neutral from Buy at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VZ Verizon
$55.09

-1.28 (-2.27%)

01/14/19
GSCO
01/14/19
DOWNGRADE
Target $110
GSCO
Neutral
Crown Castle downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Brett Feldman downgraded Crown Castle (CCI) to Neutral and lowered his price target for the shares to $110 from $116. The analyst believes tower stocks are appropriately priced given his expectations for growth in 2019. "Near-peak growth expectations" are priced in at current share levels, Feldman tells investors in a research note. The analyst also laid his top picks in Americas Telecom Services. His favorite defensive stock is Verizon (VZ), his favorite value stock is Altice USA (ATUS), his most catalyst driven idea is Zayo Group (ZAYO) and his top data center operator is Equinix (EQIX).
01/25/19
HSBC
01/25/19
DOWNGRADE
Target $24
HSBC
Reduce
Dish downgraded to Reduce from Hold at HSBC
HSBC analyst Sunil Rajgopal downgraded Dish (DISH) to Reduce from Hold and cut his price target on the shares to $24 from $38, advocating that investors choose "sturdy carriers" such as Verizon (VZ), T-Mobile (TMUS), AT&T (T) and Comcast (CMCSA). For 2019, Rajgopal expects more fragmentation in the content/pay-TV business as more players enter the OTT content market and he expects the pay TV base to shrink further.
01/23/19
MKMP
01/23/19
NO CHANGE
Target $7.5
MKMP
Buy
Nokia Q4 earnings should be solid, says MKM Partners
MKM Partners analyst Michael Genovese kept his Buy rating and $7.50 price target on Nokia (NOK) ahead of its Q4 results, saying that earnings should be solid with evidence of 5G contribution, even though the outlook on its potential "won't settle the debate". The analyst notes that T-Mobile's (TMUS) 5G network build demand should also yield a good Q1 outlook with added contribution coming from the accelerated 5G plans from KT (KT) and SK Telecom in South Korea. Genovese adds that the 5G debate centers around investment plans by AT&T (T) and Verizon (VZ), but his checks indicate that the former has not made any final decisions on the timing.
01/08/19
SBSH
01/08/19
NO CHANGE
SBSH
Verizon's 'strong' Q4 net adds bode well for sales growth, says Citi
Citi analyst Michael Rollins says Verizon's "strong" postpaid phone net additions for Q4 in a measured promotional environment bode well for the company's sales growth and cash flow as well as the broader wireless category. The analyst remains a buyer of Verizon shares as he sees further upside from better wireless performance, cost cutting and 5G.
MMM 3M
$193.20

-2.71 (-1.38%)

01/04/19
MSCO
01/04/19
NO CHANGE
Target $210
MSCO
Equal Weight
Morgan Stanley says dental survey negative for Align, positive for Straumann
Morgan Stanley analyst Steve Beuchaw noted that the firm surveyed 30 dentists and 42 orthodontists in the U.S. and said the results points to slower aligner mix shift and emerging share movements, both of which he said are negative for Align Technology (ALGN). He further points out that the survey was run during 4Q, in advance of the full launch of competing products from 3M (MMM), Danaher (DHR) and Dentsply Sirona (XRAY). Given the survey findings, Beuchaw cut his U.S. volume estimates for Align by 400bps for 2019 and lowered his price target on the stock to $210 from $300 to account for lower estimates and a lower market multiple. He maintains an Equal Weight rating on Align Technology shares. Beuchaw added that the survey was positive for Straumann (STMN), which is covered by Michael Jungling. While investors tend to focus on new entrants from the other three mentioned above, ClearCorrect with support from Straumann was the bigger share winner prospectively in the survey, Beuchaw tells investors.
01/15/19
JPMS
01/15/19
NO CHANGE
Target $158
JPMS
Underweight
JPMorgan's Tusa remains negative on 3M, cuts target to $158
JPMorgan analyst Stephen Tusa lowered his price target for 3M to $158 from $178 and keeps an Underweight rating on the shares. The analyst sees a "fundamental disconnect" between investor perception of the company's business quality, and quality of its growth. The latter is what ultimately drives the multiple, which should be lower, Tusa tells investors in a research note. Despite 3M's "consistent misses," even with a solid economic backdrop in 2018, the multiple has expanded from recent lows, and expectations for growth remain too high, claims Tusa, who says he remains negative on the shares. The analyst cut his estimates for 2019/2020 below the consensus.
01/15/19
JPMS
01/15/19
NO CHANGE
JPMS
Neutral
GE risk/reward unfavorable into Q4 report, says JPMorgan's Tusa
JPMorgan analyst Stephen Tusa says the risk/reward on shares of General Electric (GE) is unfavorable into the company's Q4 earnings report. GE shares have bounced over the last month, outperforming the group by over 3,000 basis points, Tusa writes in a research note previewing earnings reports for the group. He believes the recent stock move "is built upon an expectation of more certainty in the path forward." Tusa thinks the focus on the earnings call should turn back to fundamentals, where he continues to see "disconnect with high level analyses from those who apparently ignore the mechanical headwinds from dilutive asset sales, a key aspect as to why FCF remains so weak." The call will "reinforce the Bear case that there is no concrete silver bullet plan, and much remains fluid, also negative," Tusa contends. He recommends Honeywell (HON) and Emerson Electric (EMR) as longs into the quarter and tells investors to avoid Johnson Controls (JCI), 3M (MMM) and Rockwell Automation (ROK). Tusa has a Neutral rating on General Electric.
01/03/19
FBCO
01/03/19
NO CHANGE
Target $220
FBCO
Outperform
3M price target lowered to $220 from $230 at Credit Suisse
Credit Suisse analyst John Walsh lowered his price target for 3M to $220 from $230 to reflect a 20bps reduction in global industrial production expectations, a 200bps reduction in energy capex driven by reduced E&P spending, and current FX rates. The analyst reiterates an Outperform rating on the shares.
LMT Lockheed Martin
$287.84

0.81 (0.28%)

01/10/19
01/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Constellation Brands (STZ) upgraded to Buy from Neutral at Goldman Sachs and to Neutral from Sell at Guggenheim. 2. Boeing (BA) upgraded to Overweight from Equal Weight at Morgan Stanley. 3. Lockheed Martin (LMT) upgraded to Buy from Hold at Vertical Group. 4. United Continental (UAL) upgraded to Overweight from Neutral at JPMorgan while Alaska Air (ALK) was upgraded to Neutral from Underweight. 5. Twitter (TWTR) double upgraded to Buy from Underperform at BofA/Merrill with analyst Justin Post citing a survey he conducted which showed Twitter penetration increased to 48% of respondents and the percentage of users reporting deceased usage fell slightly. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/19
01/10/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ship Finance (SFL) initiated with a Neutral at B. Riley FBR. 2. Wipro (WIT) initiated with a Hold at Deutsche Bank. 3. Boeing (BA), Lockheed Martin (LMT), and Raytheon (RTN) were initiated with a Positive at Susquehanna while Northrop Grumman (NOC) and General Dynamics (GD) were initiated with a Neutral. 4. Dollar General (DG) initiated with an Outperform at BMO Capital while Dollar Tree (DLTR) was initiated with a Market Perform. 5. Verint (VRNT) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/19
01/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Lockheed Martin (LMT) downgraded to Equal Weight from Overweight at Morgan Stanley. 2. JetBlue (JBLU) downgraded to Neutral from Overweight at JPMorgan with analyst Jamie Baker lowering his price target for the shares to $18 from $20. 3. Weatherford (WFT) downgraded to Market Perform from Outperform at BMO Capital with analyst Daniel Boyd saying the stock represents a "call-option on the oil cycle," but sees that option "suffering from time decay" and an adverse macro environment. 4. Yelp (YELP) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Brian Nowak saying he identified three building revenue headwinds that he believes will lead to negative revisions and underperformance of the stock. 5. Dollar Tree (DLTR) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh saying he now views shares as fully valued and sees the case for upside as less attractive. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/19
SUSQ
01/10/19
INITIATION
Target $321
SUSQ
Positive
Lockheed Martin initiated with a Positive at Susquehanna
Susquehanna analyst Charles Minervino initiated Lockheed Martin with a Positive rating as he believes it should be a prime beneficiary of strong global defense spending. He expects its earnings growth will drive free cash flow generation in the coming years, providing opportunities for additional dividend increases, debt reduction, share repurchases and potential acquisitions. Minervino has a $321 price target on Lockheed Martin shares.
DHR Danaher
$106.01

-0.3 (-0.28%)

12/26/18
ARGS
12/26/18
NO CHANGE
Target $115
ARGS
Buy
Danaher's recent selloff offers 'buying opportunity', says Argus
Argus analyst John Eade kept his Buy rating and $115 price target on Danaher, saying the recent sell-off in its stock price represents a "buying opportunity". The analyst notes that while the stock has outperformed the market over the past 3 months, it is still down about 13% from its all time highs even though the company has recently offered a "transparent view" into its financials expected for 2019. Eade also cites Danaher management' track record of generating cash flows while increasing dividend at a double digit rate, adding that its multiple of 23.7-times expected forward earnings is within its normal historical range.
01/02/19
NEED
01/02/19
INITIATION
Target $114
NEED
Buy
Danaher initiated with a Buy at Needham
Needham analyst Stephen Unger started Danaher with a Buy rating and $114 price target. The company is one of only two major consolidators within the Life Science Tools sector, which continues to deliver "strong secular growth," says the analyst.
10/01/18
JPMS
10/01/18
NO CHANGE
JPMS
GE 'negative surprise' raises questions about serious issues, says JPMorgan
JPMorgan analyst Stephen Tusa said the timing and format of GE's (GE) CEO change announcement is a negative surprise that raises questions as to whether there are "serious issues at play." While the selection of ex-Danaher (DHR) CEO Larry Culp is a positive for investor confidence and the change brings the company a step closer to a real reset, the details on how potentially bad things actually are have not been shared and Tusa sees a dividend cut and potential equity raise as likely, he tells investors. The analyst maintains a $10 price target and Underweight rating on GE shares, which are up 97c, or 8.5%, to $12.26 in afternoon trading.
BIIB Biogen
$329.68

-7.12 (-2.11%)

01/03/19
PIPR
01/03/19
NO CHANGE
PIPR
Piper sees Alexion, Biogen as potential targets after Celgene buyout
Piper Jaffray analyst Christopher Raymond remains "bullish on biotech" in the wake the announced acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) for $74B in cash and stock, representing a 54% premium from yesterday's close. In a research note titled "Bristol for CELG - In Retrospect, it Makes Perfect Sense," Raymond says the market is likely to ask "who's next?" Among large-caps, Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) would seem to make sense as potential targets, as well as BioMarin (BMRN), Raymond writes. And while any smid cap could likely be seen as a take-out candidate, Aimmune Therapeutics (AIMT), Deciphera Pharmaceuticals (DCPH) and Rigel Pharmaceuticals (RIGL) "in particular could make sense to any strategic buyer," adds the analyst.
01/01/19
PIPR
01/01/19
NO CHANGE
Target $400
PIPR
Overweight
Biogen raised prices on MS drugs meaningfully today, says Piper Jaffray
According to Wolters Kluwer Health, Biogen took "meaningful" price increases across its multiple sclerosis franchise effective January 1, 2019, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "Starts The New Year Off With Spate of Price Increases." The timing and magnitudes of the increases are consistent with Biogen's established pattern, adds the analyst. Raymond, however, finds the company's increases this year notable, "especially in an environment of increasing drug pricing scrutiny on both the political and policy front." Biogen took a price increase of 6% for Tecfidera, 3.5% for Tysabri and 2% each for Avonex and Plegridy, he explains. Given President Trump's Drug Pricing Blueprint and his willingness to call out individual companies for price increases, the analyst thinks some investors will be surprised by Biogen's 2019 increases. He remains a buyer of Biogen shares with an Overweight rating and $400 price target. The stock closed Monday up $7.40 to $300.92.
12/21/18
12/21/18
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) initiated with an Overweight at Piper Jaffray. 2. Biogen (BIIB) initiated with a Buy at BTIG. 3. Allena Pharmaceuticals (ALNA) assumed with a Buy at B. Riley FBR. 4. WWE (WWE) initiated with a Hold at Loop Capital. 5. Applied Materials (AMAT) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/21/18
BTIG
12/21/18
INITIATION
Target $362
BTIG
Buy
BTIG starts Biogen with Buy rating, $362 price target
BTIG analyst Thomas Shrader last night initiated coverage of Biogen with a Buy rating and $362 price target. The analyst sees the company as well positioned with a "history of investing in imaging approaches for R&D, a hard-nosed business culture, a focus on neuroscience, and a cash-cow stable" of multiple sclerosis drugs. Further, Shrader expects "excitement to build over the aducanumab" story as we near the first Phase 3 readouts.
AGN Allergan
$158.72

-1.92 (-1.20%)

01/24/19
PIPR
01/24/19
NO CHANGE
Target $73
PIPR
Overweight
Piper values Glaukos pipeline at $60, says only $10 in shares today
Piper Jaffray analyst Matt O'Brien reiterates an Overweight rating on Glaukos (GKOS) with a 73 price target after conducting a deep dive on the company's pipeline. The analyst finds iDose most compelling, which he believes "unlocks a large market of more than 4 million eyes." The device is superior to competition, most notably Allergan's (AGN) Bimatoprost SR on the safety front, and will likely demonstrate greater device duration as well, O'Brien tells investors in a research note. Further, he views Supra as a favorable near-term risk/reward opportunity given the low expectations in the suprachoroidal space following the CyPass withdrawal. O'Brien values the entire Glaukos pipeline at $60 per share and believes only $10 is in the stock today.
01/28/19
STFL
01/28/19
INITIATION
Target $27
STFL
Buy
Evolus initiated with a Buy at Stifel
Stifel analyst Annabel Samimy started Evolus (EOLS) with a Buy rating and $27 price target, citing her view of the potential for Jeuveau to be an identical, drop-in, "frictionless" replacement for Allergan's (AGN) Botox with "a marketing angle and pedigree that no other toxin has claimed before."
01/28/19
STFL
01/28/19
INITIATION
Target $50
STFL
Buy
Revance initiated with a Buy at Stifel
Stifel analyst Annabel Samimy initiated Revance (RVNC) with a Buy rating and $50 price target, citing her view that the company's daxibotulinumtoxinA represents "one of the first truly novel neurotoxin formulations" and potentially offers six-month duration of effect as compared to the 3-4 months for Allergan's (AGN) Botox and competitors' agents.
01/24/19
JPMS
01/24/19
UPGRADE
Target $13
JPMS
Neutral
JPMorgan upgrades Ironwood to Neutral with $13 price target
JPMorgan analyst Eric Joseph upgraded Ironwood Pharmaceuticals (IRWD) to Neutral from Underweight and raised his price target for the shares to $13 from $11. While incremental color on Linzess price and growth expectations may emerge when Allergan (AGN) reports next week, the current 2019 consensus estimates are appropriately conservative, Joseph tells investors in a research note. Further, the analyst anticipates "ongoing volatility near-term" driven by interest in Ironwood's separation into two companies, which is completing in the first half of 2019.
HCA HCA Healthcare
$131.62

-1.27 (-0.96%)

01/14/19
SPHN
01/14/19
INITIATION
Target $143
SPHN
Overweight
HCA Healthcare initiated with an Overweight at Stephens
Stephens analyst Scott Fidel initiated coverage of 11 Managed Care and Healthcare Facilities stocks, telling investors that overall he is constructive on managed care and selective on hospitals. He started HCA Healthcare with an Overweight rating and $143 price target, noting that its fundamental performance accelerated across all key metrics in 2018 and the company has already signaled that EBITDA growth trends could again exceed its long-term targets in 2019.
01/04/19
JEFF
01/04/19
NO CHANGE
JEFF
Jefferies more cautious on Healthcare Services group for 2019
After strong performance in 2018, Jefferies analyst Brian Tanquilut is more cautious on the Healthcare Services group for 2019 given his belief that sales growth will be "tepid" for most providers as overall utilization flattens out and increased market volatility drives greater scrutiny of debt levels. Given this backdrop, companies that can deliver positive organic or acquisition-driven growth with solid balance sheets should outperform, Tanquilut tells investors in a research note. His top picks in the space are Addus HomeCare (ADUS), Amedisys (AMED), AMN Healthcare (AMN), Encompass Health (EHC), HCA Healthcare (HCA), LHC Group (LHCG) and RadNet (RDNT).
01/03/19
DBAB
01/03/19
INITIATION
Target $140
DBAB
Buy
HCA Healthcare initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Pito Chickering started HCA Healthcare with a Buy rating and $140 price target. The analyst initiated coverage on Healthcare Facilities with a constructive view saying the sector is "relatively defensive" in slowing business cycles and that company cash flows "provide downside protection in volatile markets."
01/24/19
BARD
01/24/19
NO CHANGE
Target $155
BARD
Outperform
HCA Healthcare elevated to Fresh Pick at Baird
Baird analyst Matthew Gillmor elevated HCA Healthcare (HCA) to Fresh Pick ahead of its Q4 report. The analyst said recent commentary from UnitedHealth (UNH) and Johnson & Johnson (JNJ) suggest Q4 patient volumes remain solid, which he thinks will translate into EBITDA upside for HCA. Gillmor reiterated his Outperform rating and $155 price target on HCA Healthcare shares.
GLW Corning
$30.37

0.02 (0.07%)

11/14/18
GUGG
11/14/18
DOWNGRADE
GUGG
Neutral
Guggenheim sees 5% iPhone drop next year, downgrades Apple to Neutral
Guggenheim analyst Robert Cihra downgraded Apple to Neutral from Buy and removed his prior $245 price target for the shares. The stock closed yesterday down $1.94 to $192.23. The average selling price of the iPhone has increased a "dramatic" $220, or 40%, over the past 10 years, reflecting its "growing value to both consumer and business markets," Cihra tells investors in a research note. The analyst points out, however, that nearly half of that increase came in fiscal 2018 alone. This makes a "period of digestion now likely," Cihra writes in a note partially titled "ASPs No Longer Enough." The analyst believes Apple's growth via average selling price is now "widely known." The iPhone's nearly 60% contribution to revenue and profits is "looking like a headwind again," says Cihra. Following early supply chain cuts, exemplified by Corning's (GLW) "softer" Q4 gorilla glass guidance back in October and this week's warnings from 3D sensing laser supplier Lumentum (LITE) and LCD supplier Japan Display, the analyst now estimates iPhone units will decline 5% year-over-year in fiscal 2019. He cut his fiscal 2019 earnings per estimate for Apple to $12.97 from $13.41 and revenue estimate to $273B from $281B.
09/20/18
ARGS
09/20/18
NO CHANGE
Target $42
ARGS
Buy
Corning price target raised to $42 from $36 at Argus
Argus analyst Jim Kelleher raised Corning's price target to $42 from $36 sayaing its positioned to leverage revenue growth into margin expansion in 2H 2018 and 2019. Kelleher said investments are now bearing fruit and is positioned for positive bottom-line comparisons for 2H 2018 and 2019.
11/29/18
SBSH
11/29/18
NO CHANGE
SBSH
Citi consumer electronics survey positive for Corning, negative for GoPro
Citi surveyed 60 retail and electronics stores in the U.S. during mid-November to inquire about promotions, sell-through, and preferences for various consumer electronics products, analyst Jim Suva tells investors in a research note. The analyst calls television the "clear winner," followed by video game accessories and wireless speakers. The results point to continued size migration to 50 inch-plus TVs and strong elasticity of demand for price promotions, says Suva. He believes this benefits Corning (GLW). The analyst also finds the video gaming accessories trends as positive for Logitech (LOGI). Fitness trackers and smartwatch trends are neutral for Fitbit (FIT) and positive for Apple (AAPL), while digital camera trends negative for GoPro (GPRO), adds Suva.
09/14/18
09/14/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Corning (GLW) upgraded to Buy from Neutral at Citi with analyst Asiya Merchant saying the shares are "poised to continue to grind higher" in the next 12-18 months as investors appreciate the company's "multiple vectors" for revenue growth, diversification and margin expansion. 2. Coca-Cola European Partners (CCE) was upgraded to Outperform at Wells Fargo and to Neutral from Negative at Susquehanna. 3. VF Corp. (VFC) upgraded to Outperform from Market Perform at Cowen with analyst John Kernan saying VF's disclosure of a 23% operating margin for Vans implies that the brand alone could generate $1B-plus in free cash flow by fiscal 2022. 4. Helmerich & Payne (HP) upgraded to Neutral from Underweight at JPMorgan with analyst Sean Meakim saying Helmerich exceeded his expectations in adapting to the upgrade cycle. 5. Parker-Hannifin (PH) upgraded to Buy from Neutral at Buckingham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PCAR Paccar
$61.30

-1.34 (-2.14%)

01/14/19
PIPR
01/14/19
NO CHANGE
PIPR
Piper names Paccar, Meritor highest conviction truck ideas
Downside risk is limited for Paccar (PCAR) and Meritor (MTOR), even if a recession is coming in 2020, Piper Jaffray analyst Alexander Potter tells investors in a research note. After examining "the degree to which truck stock valuations have fallen far enough to reflect a worst-case (recessionary) scenario," the analyst names Paccar and Meritor his highest conviction truck ideas. He believes that if expectations for a recession continue rising, stocks like Allison Transmission (ALSN) and Navistar (NAV) "would probably fare less well." These stocks would need to fall by 39% and 44%, respectively, before they fully reflected a recessionary outlook, says Potter.
01/10/19
JPMS
01/10/19
NO CHANGE
JPMS
JPMorgan changes ratings in Machinery ahead of Q4 earnings
JPMorgan analyst Ann Duignan says her U.S. Machinery coverage universe underperformed the broader market in 2018 as investors grew more concerned about the potential for a U.S. recession led by rising interest rates on top of a slowdown in international growth. As a result, the group looks "cheap" relative to the S&P 500 Index, Duignan tells investors in a research note. She also believes the selloff has been overdone for a number of stocks in her coverage. That said, the analyst thinks Eurozone growth is one of the biggest risks facing companies in space. As such, she suggests investors minimize exposure to companies with an outsized European Union mix. With this backdrop, Duignan upgraded both Oshkosh (OSK) and Trimble (TRMB) to Overweight from Neutral on valuation. She also downgraded Paccar (PCAR), Wabco (WBC) and Illinois Tool Works (ITW) to Underweight from Neutral given their exposure to Europe.
01/10/19
JPMS
01/10/19
DOWNGRADE
Target $54
JPMS
Underweight
Paccar downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Ann Duignan downgraded Paccar to Underweight and lowered her price target for the shares to $54 from $63.
01/24/19
OTRG
01/24/19
DOWNGRADE
OTRG
Mixed
Paccar downgraded to Mixed from Positive at OTR Global
OTR Global downgraded Paccar to Mixed from Positive following checks with industry sources that indicate a slowing freight demand and order cancellations in Western Europe. Further, the firm's analyst said oversupply is causing weakness in European used truck prices, which are down 1%-4% quarter-over-quarter.
ROK Rockwell Automation
$163.53

-2.78 (-1.67%)

01/25/19
01/25/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Flir Systems (FLIR) upgraded to Outperform from Neutral at Baird with analyst Peter Arment saying defense contract wins that are providing good visibility and current valuation, which provides a good risk/reward. 2. McCormick (MKC) upgraded to Hold from Sell at Deutsche Bank and to Overweight from Equal Weight at Consumer Edge. 3. Rockwell Automation (ROK) upgraded to Buy from Reduce at HSBC with analyst Michael Hagmann saying he views the correction in shares as "overdone" and said Rockwell offers robust secular automation fundamentals, strong cash flow generation, and best-in-class ROIC, with potential for end market improvement in FY19. 4. Triumph Group (TGI) upgraded to Outperform from Market Perform at Cowen with analyst Cai von Rumohr citing its Global 7500 program as it will reduce the company's risk, bolster 2020 free cash flow, and shift its mix to profitable sectors. 5. Carnival (CCL) upgraded to Outperform from Neutral at Macquarie with analyst Paul Golding citing valuation and favorable exposure to oil prices. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/25/19
HSBC
01/25/19
UPGRADE
HSBC
Buy
Rockwell Automation upgraded to Buy from Reduce at HSBC
HSBC analyst Michael Hagmann double upgraded Rockwell Automation to Buy from Reduce and raised its price target to $175 from $165. Hagmann views the correction in shares as "overdone" and said Rockwell offers robust secular automation fundamentals, strong cash flow generation, and best-in-class ROIC, with potential for end market improvement in FY19.
01/18/19
BMOC
01/18/19
INITIATION
Target $185
BMOC
Outperform
Rockwell Automation initiated with an Outperform at BMO Capital
BMO Capital analyst R. Scott Graham initiated Rockwell Automation with an Outperform rating and a price target of $185. The analyst believes that the company offers a "long path for sales growth" that is above average rate under its Connected Enterprise vision. Graham also points to Rockwell Automation's "lower beta" and "well-conceived strategies" to support its competitive advantages and investment. The analyst sees the stock offering a long-term double-digit earnings growth profile.
NUE Nucor
$58.45

0.33 (0.57%)

01/22/19
JEFF
01/22/19
DOWNGRADE
Target $24
JEFF
Hold
Jefferies downgrades U.S. Steel to Hold on guidance risk
Jefferies analyst Seth Rosenfeld downgraded U.S. Steel to Hold from Buy and lowered his price target for the shares to $24 from $38. "Poor" Q4 earnings and Q1 guides will begin to reflect the extent of recent steel margin weakness, Rosenfeld tells investors in a research note. The analyst, while remaining "constructive" on the broader Steel sector, downgraded U.S. Steel to reflect guidance risk and "increasingly challenged" long-term prospects. With both U.S. and European flat steel margins drifting lower, drivers for a "meaningful recovery" at the company are "hard to identify," says the analyst. As such, he believes U.S. Steel's 2019 EBITDA guidance risks disappointing consensus expectations. Rosenfeld's top picks in the U.S. are Nucor (NUE), Commercial Metals (CMC), Steel Dynamics (STLD), Reliance Steel (RS) and Cleveland-Cliffs (CLF).
01/28/19
01/28/19
UPGRADE
Target $21

Equal Weight
Morgan Stanley ups U.S. Steel to Equal Weight on near-term steel price bounce
As previously reported, Morgan Stanley analyst Piyush Sood upgraded U.S. Steel (X) to Equal Weight from Underweight as he thinks the market has sufficiently priced in operational and pricing concerns given the stock's 20% underperformance compared to "mini mills" Steel Dynamics (STLD), Nucor (NUE) and Commercial Metals (CMC) over the last six months. While he thinks a seasonal pickup in U.S. demand should help put a floor under steel pricing, he would look to fade any 3-6 month steel price and sentiment rally, Sood added. He lowered his price target on U.S. Steel shares to $21 from $30.
01/08/19
COWN
01/08/19
INITIATION
Target $62
COWN
Outperform
Nucor initiated with an Outperform at Cowen
Cowen analyst Tyler Kenyon initiated Nucor with an Outperform and $62 price target.
01/08/19
01/08/19
UPGRADE
Target $70

Outperform
Credit Suisse says Nucor 'oversold,' upgrades to Outperform
As previously reported, Credit Suisse analyst Curt Woodworth upgraded Nucor to Outperform from Neutral as he believes the stock is oversold relative to medium term fundamentals. While the U.S. sheet markets are weak, the long product and plate markets are very strong and account for about 60% of total volume at Nucor, he contends. Further, Woodworth argues that while Nucor's capital spending profile the next few years is high, the company will still have plenty of bandwidth to repurchase shares given Big River is off the table. The analyst also lowered his price target on the shares to $70 from $74.
HRS Harris
$142.88

-0.6 (-0.42%)

11/13/18
LEHM
11/13/18
UPGRADE
Target $181
LEHM
Overweight
Harris upgraded to Overweight from Equal Weight at Barclays
Barclays analyst David Strauss upgraded Harris Corp (HRS). to Overweight while lowering his price target for the shares to $181 from $189. The analyst sees the merger with L3 Technologies (LLL) enhancing the company's growth characteristics.
12/13/18
JEFF
12/13/18
NO CHANGE
Target $170
JEFF
Buy
Jefferies lowers Harris target to $170, L3 target to $205
Jefferies analyst Sheila Kahyaoglu lowered her price target for Buy-rated Harris (HRS) to $170 from $184 and for Hold-rated L3 Technologies (LLL) to $205 from $224. After a deep dive into the combined company, the analyst sees the most significant opportunities in Broadband Comms and Night Vision. Overall, her assumptions are for 6% growth, in line with the fiscal 2017-2021 budget, with growth front-end-loaded. Cost take-out should translate to revenue growth over the long term, Kahyaoglu tells investors in a research note.
11/02/18
JPMS
11/02/18
DOWNGRADE
Target $240
JPMS
Neutral
L3 Technologies downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Seth Seifman downgraded L3 Technologies (LLL) to Neutral and lowered his price target for the shares to $240 from $245. The analyst views Harris (HRS) as the better way to gain exposure to the proposed merger. He keeps an Overweight rating on Harris with a $190 price target.
11/13/18
LEHM
11/13/18
UPGRADE
Target $181
LEHM
Overweight
Barclays upgrades Harris to Overweight ahead of L3 merger
Barclays analyst David Strauss upgraded Harris Corp (HRS). to Overweight while lowering his price target for the shares to $181 from $189. The analyst forecasts "outsized growth" for Harris, even prior to its pending merger with L3 Technologies (LLL). He believes his thesis on standalone Harris, which reflects "strong" revenue growth combined with "commercial-like" operating leverage and "significant" capital deployment post deleveraging and pension, can only be enhanced with the operational improvement opportunity that the merger brings. Strauss estimates the combined company will generate $2B in free cash flow by deal close, leaving it "only" 1.5 times net levered, "immediately allowing for aggressive share repurchase."
LLL L3 Technologies
$183.86

-0.635 (-0.34%)

DOV Dover
$79.19

-0.31 (-0.39%)

01/10/19
UBSW
01/10/19
UPGRADE
UBSW
Buy
Dover upgraded to Buy from Neutral at UBS
01/10/19
UBSW
01/10/19
UPGRADE
Target $91
UBSW
Buy
UBS sees 20% upside in Dover, upgrades shares to Buy
UBS analyst Steven Winoker upgraded Dover to Buy from Neutral with a $91 price target. Better than forecasted earnings as well as a valuation re-rating will contribute to ~20% appreciation in the shares over the next 12 months, Winoker tells investors in a research note. The analyst's 2019 estimates are 5% above consensus and he believes the stock's upside/downside ration is 3:1. Following asset sales and the Apergy spinoff, management has an opportunity to rebrand the Dover image, Winoker says.
01/08/19
WOLF
01/08/19
UPGRADE
WOLF
Outperform
Dover upgraded to Outperform from Peer Perform at Wolfe Research
12/18/18
MSCO
12/18/18
DOWNGRADE
Target $89
MSCO
Equal Weight
Dover assumed at Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Joshua Pokrzywinski assumed coverage of Dover at Equal Weight, down from the firm's prior Overweight rating, stating that he believes the company has significant margin upside across the portfolio, but rightsizing and shifting its footprint will take time and can come with execution risks. He also sees Refrigeration & Food Equipment markets continuing to decelerate into next year, Pokrzywinski noted He set an $89 price target on Dover shares, down from the firm's prior $94 target.
AOS A.O. Smith
$48.18

0.6 (1.26%)

11/27/18
KEYB
11/27/18
UPGRADE
KEYB
Overweight
A.O. Smith upgraded to Overweight from Sector Weight at KeyBanc
11/19/18
SPHN
11/19/18
INITIATION
Target $50
SPHN
Equal Weight
A.O. Smith initiated with an Equal Weight at Stephens
Stephens analyst Rob McCarthy stared A.O. Smith with an Equal Weight rating and $50 price target, stating that he likes its strong execution but is "mindful" of the company's outsized exposure to China and the headline risks around trade and tariffs.
11/06/18
BARD
11/06/18
NO CHANGE
Target $54
BARD
Outperform
A.O. Smith remains a long-term growth opportunity, says Baird
Baird analyst Michael Halloran said he remains a buyer of A.O. Smith shares as he continues to believe organic 2021 earnings power will grow. When combined with its premium financial profile and net-cash positive balance sheet, the current valuation represents an attractive entry point, said Halloran, who reiterated his Outperform rating and $54 price target on A.O. Smith.
11/27/18
11/27/18
UPGRADE
Target $53

Overweight
A.O. Smith upgraded to Overweight at KeyBanc on 'overstated' China risk
As previously reported, KeyBanc analyst Jeffrey Hammond upgraded A.O. Smith to Overweight from Sector Weight, with a $53 price target. The analyst now sees greater likelihood for multiple expansion over prevailing quarters, as China risk, while still prevalent, appears overstated at current valuation. In addition, Hammond expects North American incrementals to more fully reflect the company's favorable price/cost positioning heading into next year.
PHM PulteGroup
$27.03

0.07 (0.26%)

01/17/19
01/17/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Electronic Arts (EA) downgraded to Hold from Buy at Jefferies with analyst Timothy O'Shea saying the company's key profit engine Ultimate Team is plateauing. 2. First Data (FDC) downgraded to Neutral from Buy at Goldman Sachs and Mizuho, to Neutral from Overweight at Atlantic Equities, and to Market Perform from Outperform at Keefe Bruyette. 3. PulteGroup (PHM) downgraded to Sell from Neutral at BTIG with analyst Carl Reichardt citing valuation, sell-side optimism, and growing margin pressure. 4. Aegon (AEG) downgraded to Sell from Neutral at Citi. 5. Patterson-UTI (PTEN) downgraded to Neutral from Overweight at JPMorgan with analyst Sean Meakim saying while the company's Q4 rig count exceeded guidance, its exposure to smaller Exploration & Production companies increases its potential rig losses in 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/11/19
BUCK
01/11/19
INITIATION
Target $30
BUCK
Neutral
PulteGroup initiated with a Neutral, valuation at a premium, says Buckingham
Buckingham analyst Megan McGrath initiated PulteGroup with a Neutral and $30 price target citing premium valuation and slowing growth.
01/11/19
01/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Activision Blizzard (ATVI), Take-Two (TTWO), Electronic Arts (EA), Glu Mobile (GLUU) were initiated with an Overweight at Stephens, while the analyst also initiated Zynga (ZNGA) and Ubisoft (UBSFY) with an Equal Weight. 2. Domino's Pizza (DPZ) initiated with an Outperform at Cowen. 3. Okta (OKTA) and Zscaler (SZ) initiated with an Overweight at Piper Jaffray. 4. Lennar (LEN), D.R. Horton (DHI) and NVR (NVR) initiated with a Buy and KB Home (KBH), PulteGroup (PHM), Hovnanian (HOV) and Toll Brothers (TOL) initiated with a Neutral at Buckingham. 5. VMware (VMW) reinstated with a Neutral at Goldman SachsThis list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/17/19
BTIG
01/17/19
DOWNGRADE
Target $23
BTIG
Sell
PulteGroup downgraded to Sell from Neutral at BTIG
BTIG analyst Carl Reichardt downgraded PulteGroup to Sell with a price target of $23 citing its valuation, sell-side optimism, and growing margin pressure. The analyst notes that the stock has recently outperformed its peer group average by 14% and now trades at a 21% premium on total book value per share basis, but expects its order growth to underperform because of its "inadequate entry-level product mix." As the company "increases incentives to move units", Reichardt expects PulteGroup shares to de-rate this year given the resulting margin pressure.
HOG Harley-Davidson
$36.61

-0.25 (-0.68%)

01/25/19
UBSW
01/25/19
NO CHANGE
Target $40
UBSW
Neutral
UBS sees risk to Harley-Davidson outlook
UBS analyst Robin Farley looked at the demographic trends shaping motorcycle demand and questions whether motorcycling has had its "cultural moment." The analyst said the survey shows aging riders are a headwind and that used bike demand has been tracking up this year while new bike sales interest is at levels below 2016. Farley sees risk to Harley-Davidson's outlook and little room for multiple expansion. She maintains her Neutral rating and $40 price target on Harley-Davidson shares.
01/17/19
LBOW
01/17/19
NO CHANGE
LBOW
Neutral
Harley-Davidson checks point to continued U.S. retail weakness, says Longbow
Longbow analyst David MacGregor said his end of quarter checks pointed to continued weakness in Harley-Davidson's U.S. retail sales. He lowered his Q4 earnings estimate by 3c to 25c per share to reflect lower shipment expectations following the checks and keeps a Neutral rating on Harley shares, adding that he projects that the company will deliver both below-consensus Q4 earnings and FY19 guidance.
12/19/18
UBSW
12/19/18
NO CHANGE
Target $40
UBSW
Neutral
Harley-Davidson checks show sales down double digits, says UBS
UBS analyst Robin Farley said her recent channel checks on Harley Davidson show retail sales for October-November are looking down double digits. The decline is worse than expectations and notable given it is against comps from hurricane disruptions the previous year. Farley maintained her Neutral rating and $40 price target on Harley-Davidson shares.
12/18/18
WELS
12/18/18
NO CHANGE
Target $40
WELS
Outperform
Harley-Davidson price target lowered to $40 from $46 at Wells Fargo
Wells Fargo analyst Timothy Conder lowered his price target for Harley-Davidson to $40 from $46 as fourteen of his nineteen Powersports Economic Indicators are decelerating, potentially confirming what he believes could be peak Powersport earnings in 2019. Further, the analyst believes forward multiples will generally be constrained to the lower quartile of historical ranges. He reiterates an Outperform rating on the shares.
PII Polaris Industries
$84.82

-2.235 (-2.57%)

01/15/19
LBOW
01/15/19
NO CHANGE
LBOW
Neutral
Longbow cuts Polaris Industries EPS estimates following end-of-quarter checks
Longbow analyst David MacGregor said in a note to investors prior to the open that his end-of quarter survey of Polaris dealer pointed to December ORV retail sales growth that was flat to up by a low single digit percentage in North America. He reduced his Q4 retail sales estimate to up low single digits following the checks and cut his EPS forecast to reflect lower ORV/Snowmobile shipments and his view that Polaris is on track to deliver below-consensus results. He keeps a Neutral rating on Polaris shares.
12/18/18
WELS
12/18/18
NO CHANGE
Target $90
WELS
Outperform
Polaris Industries price target lowered to $90 from $115 at Wells Fargo
Wells Fargo analyst Timothy Conder lowered his price target for Polaris Industries to $90 from $115 as fourteen of his nineteen Powersports Economic Indicators are decelerating, potentially confirming what he believes could be peak Powersport earnings in 2019. Further, the analyst believes forward multiples will generally be constrained to the lower quartile of historical ranges. He reiterates an Outperform rating on the shares.
12/10/18
RILY
12/10/18
DOWNGRADE
Target $99
RILY
Neutral
Polaris Industries downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Eric Wold downgraded Polaris Industries to Neutral and lowered his price target for the shares to $99 from $126. The analyst cites "increased murkiness" around the China tariff situation as the reason for the downgrade.
10/26/18
RAJA
10/26/18
UPGRADE
RAJA
Strong Buy
Polaris Industries upgraded to Strong Buy from Outperform at Raymond James
KNX Knight-Swift
$30.07

-0.71 (-2.31%)

01/22/19
DBAB
01/22/19
NO CHANGE
DBAB
Buy
Deutsche Bank names Werner short-term investment idea
Deutsche Bank analyst Amit Mehrotra placed a "Catalyst Call" on Werner Enterprises (WERN) as a short-term investment idea. Despite the recent rally in U.S. Transportation stocks, Werner shares still trade at a "meaningful discount" to fair value at this point in the cycle, Mehrotra tells investors in a research note. He points out that the stock has significantly lagged peer Knight-Swift (KNX) year-to-date. The analyst keeps a Buy rating on Werner.
01/02/19
SPHN
01/02/19
NO CHANGE
SPHN
CBS, Global Payments, Union Pacific among Stephens' best ideas for 2019
Stephens released its Best Ideas list for 2019, noting that over the last 13 years its Best Ideas list has outperformed the Russell 2000 by an average of 300 bps. Of note, six of the firm's 30 analysts listed "cash" as their best idea for this year. Among the rest, the picks included: Landstar System (LSTR), Enova (ENVA), RealPage (RP), FMC Corporation (FMC), Avanos (AVNS), Knight-Swift (KNX), CBS (CBS), Vulcan Materials (VMC), Encompass Health (EHC), Watsco (WSO), Global Payments (GPN), O'Reilly Automotive (ORLY), NeoGenomics (NEO), Continental Resources (CLR), Union Pacific (UNP), Ametek (AME), Wintrust Financial (WTFC), Helmerich & Payne (HP), Penske Automotive (PAG), Signature Bank (SBNY), Noble Energy (NBL), Origin Bancorp (OBNK), GrubHub (GRUB) and CenterState Bank (CSFL).
01/22/19
LOOP
01/22/19
NO CHANGE
Target $47
LOOP
Buy
Knight-Swift generating stronger Swift margin recovery, says Loop Capital
Loop Capital analyst Jeffrey Kauffman kept his Buy rating and $47 price target on Knight-Swift but also raised his FY18 EPSS view to $2.46 from $2.29. The analyst cites the company's "stronger-than-expected margin recovery in the former Swift businesses, as well as lower operating costs and higher revenues per mile at the former Knight properties." Kauffman adds that while the Knight and Swift merger of 2017 had its challenges in the pace of materialized synergies, signs of progress in the recent quarter's results give investors an opportunity to take advantage of the pullback in Knight-Swift stock price.
01/22/19
WOLF
01/22/19
DOWNGRADE
WOLF
Peer Perform
Knight-Swift downgraded to Peer Perform from Outperform at Wolfe Research
GPK Graphic Packaging
$12.17

0.02 (0.16%)

01/07/19
SBSH
01/07/19
UPGRADE
Target $27
SBSH
Buy
Silgan Holdings upgraded to Buy from Neutral at Citi
Citi analyst Anthony Pettinari upgraded Silgan Holdings (SLGN) to Buy with an unchanged price target of $27. The analyst says the upgrade reflects a more defensive positioning for Paper & Packaging in 2019. Following 2018's underperformance there are some supportive signs on valuation, with the Packagers' disconnect from Consumer Staples "especially noteworthy," Pettinari tells investors in a research note. Crown Holdings (CCK), Berry Global (BERY) and Graphic Packaging (GPK) are his top picks for 2019.
12/27/18
12/27/18
NO CHANGE

Stephens to keep GrubHub, RealPage, Vulcan Materials on 2019 Best Ideas list
Stephens said that it plans to publish a complete updated 2019 Best Ideas list on January 2, but in anticipation it shared the names that are being dropped and the three stocks that will remain on the list. The holdovers are GrubHub (GRUB), RealPage (RP) and Vulcan Materials (VMC). The stocks being removed include Boston Scientific (BSX), Brookdale Senior Living (BKD), Conn's (CONN), CoStar Group (CSGP), Curo Group (CURO), FedEx (FDX), First Financial Bancorp (FFBC), Graphic Packaging (GPK), Hub Group (HUBG), Keane Group (FRAC), KeyCorp (KEY), LKQ Corp. (LKQ), Myriad Genetics (MYGN), SVB Financial (SIVB), Triumph Bancorp (TBK), TrueCar (TRUE) and Union Bankshares (UBSH).
12/11/18
GHSC
12/11/18
INITIATION
GHSC
Neutral
Graphic Packaging initiated with a Neutral at Seaport Global
Seaport Global analyst Mark Weintraub initiated Graphic Packaging with a Neutral citing mixed catalysts as price improvement is being undercut by slippage in renewed sales contracts.
01/04/19
UBSW
01/04/19
INITIATION
Target $12
UBSW
Neutral
Graphic Packaging initiated with a Neutral at UBS
UBS analyst Edlain Rodriguez initiated Graphic Packaging with a Neutral rating and $11.50 price target.
CVLT Commvault
$61.60

-0.65 (-1.04%)

10/31/18
KEYB
10/31/18
DOWNGRADE
KEYB
Sector Weight
Commvault downgraded to Sector Weight from Overweight at KeyBanc
10/30/18
JMPS
10/30/18
DOWNGRADE
JMPS
Market Perform
Commvault downgraded to Market Perform from Outperform at JMP Securities
07/24/18
MUFG
07/24/18
NO CHANGE
Target $59
MUFG
Neutral
Commvault price target raised to $59 at MUFG on broader rerating
MUFG analyst Stephen Bersey kept his Neutral rating on Commvault after the company's mixed Q2 earnings but raised his price target to $59 from $57 to reflect the "broad tech-market re-rating". The analyst believes the company's quarter was generally "weak", driven by "derivative impacts from its restructuring efforts and continued poor sales performance", but also notes that its end markets are robust and the products are "high quality".
07/25/18
JEFF
07/25/18
NO CHANGE
Target $80
JEFF
Buy
Commvault has more value than shares indicate, says Jefferies
Commvault Systems yesterday morning reported "another lackluster" quarter and its guidance implies more of the same, Jefferies analyst John DiFucci tells investors in a post-earnings research note titled "More to Do." The analyst, however, keeps a Buy rating on the shares with an $80 price target. He believes there's greater value at the company than what is reflected in the shares. "Outside help could unlock that value in this case," DiFucci writes.
EAT Brinker
$47.38

0.87 (1.87%)

01/07/19
STFL
01/07/19
UPGRADE
STFL
Buy
Brinker upgraded to Buy from Hold at Stifel
01/08/19
RAJA
01/08/19
UPGRADE
Target $53.5
RAJA
Outperform
Brinker upgraded to Outperform on rising comp expectations at Raymond James
As previously reported, Raymond James upgraded Cheesecake Factory to Outperform from Market Perform and established a $53.50 price target. Analyst Brian Vaccaro raised Q2 earnings estimate to 94c from 86c, above consensus of 88c, to reflect rising comp expectations at Chili's, and raised his Q3 comp estimate to 1.5% from 1%. Vaccaro said Brinker's low valuation, high short interest, and potential Q2 upside to earnings and comps creates a positive risk/reward profile over the next few months.
01/08/19
RAJA
01/08/19
UPGRADE
RAJA
Outperform
Brinker upgraded to Outperform from Market Perform at Raymond James
01/07/19
01/07/19
UPGRADE
Target $57

Buy
Brinker upgraded to Buy on expected same store sales growth at Stifel
As previously reported, Stifel analyst Chris O'Cull upgraded Brinker to Buy from Hold as he thinks recent traffic improvement at Chili's appear to be from structural changes to the menu and investments in value, food quality, and an improved take-out experience. He believes many investors remain skeptical of Chili's ability to sustain same restaurant sales gains, so greater confidence in the outlook could be the impetus for an improved valuation, O'Cull tells investors. He maintains a $57 price target on Brinker shares.

TODAY'S FREE FLY STORIES

FTNW

FTE Networks

$1.15

0.28 (32.18%)

14:52
10/23/19
10/23
14:52
10/23/19
14:52
Hot Stocks
Breaking Hot Stocks news story on FTE Networks »

FTE Networks Inc trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$254.68

-0.94 (-0.37%)

14:49
10/23/19
10/23
14:49
10/23/19
14:49
Options
Tesla options imply 11.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

KR

Kroger

$24.96

0.1 (0.40%)

14:45
10/23/19
10/23
14:45
10/23/19
14:45
Options
Kroger call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

14:45
10/23/19
10/23
14:45
10/23/19
14:45
General news
Treasury's $41 B 5-year auction was well supported »

Treasury's $41 B…

GSK

GlaxoSmithKline

$43.20

0.69 (1.62%)

, MYGN

Myriad Genetics

$32.14

-0.15 (-0.46%)

14:38
10/23/19
10/23
14:38
10/23/19
14:38
Hot Stocks
FDA approves niraparib for HRD-positive advanced ovarian cancer »

On October 23, the Food…

GSK

GlaxoSmithKline

$43.20

0.69 (1.62%)

MYGN

Myriad Genetics

$32.14

-0.15 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 30

    Oct

  • 06

    Nov

  • 13

    Nov

  • 07

    Dec

TSLA

Tesla

$253.92

-1.7 (-0.67%)

14:27
10/23/19
10/23
14:27
10/23/19
14:27
On The Fly
Fly Intel: What to watch in Tesla earnings report »

Tesla (TSLA) is scheduled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

14:25
10/23/19
10/23
14:25
10/23/19
14:25
Conference/Events
Senate Caucus on International Narcotics Control holds a hearing »

The Caucus holds a…

ALKS

Alkermes

$19.30

0.88 (4.78%)

14:22
10/23/19
10/23
14:22
10/23/19
14:22
Recommendations
Alkermes analyst commentary  »

Alkermes making some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

TSLA

Tesla

$253.68

-1.94 (-0.76%)

14:22
10/23/19
10/23
14:22
10/23/19
14:22
Periodicals
Tesla sued over Model S door handle malfunction, CCN says »

The family of a man who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FITB

Fifth Third

$28.11

-0.195 (-0.69%)

14:20
10/23/19
10/23
14:20
10/23/19
14:20
Options
Calls lead puts 8:1 in Fifth Third Bancorp as writer opens position »

Calls lead puts 8:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 29

    Oct

IBM

IBM

$134.05

0.02 (0.01%)

, GOOGL

Alphabet Class A

$1,252.30

11.22 (0.90%)

14:18
10/23/19
10/23
14:18
10/23/19
14:18
Periodicals
Google says computer achieves 'quantum supremacy,' Reuters reports »

Alphabet's Google…

IBM

IBM

$134.05

0.02 (0.01%)

GOOGL

Alphabet Class A

$1,252.30

11.22 (0.90%)

GOOG

Alphabet

$1,253.87

11.09 (0.89%)

MSFT

Microsoft

$136.15

-0.24 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 21

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/23/19
10/23
14:17
10/23/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/23/19
10/23
14:16
10/23/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$54.51

0.64 (1.19%)

, WBA

Walgreens Boots Alliance

$54.40

-0.93 (-1.68%)

14:12
10/23/19
10/23
14:12
10/23/19
14:12
On The Fly
Coca-Cola upgrade, Walgreens downgrade among today's top analyst calls »

Check out today's top…

KO

Coca-Cola

$54.51

0.64 (1.19%)

WBA

Walgreens Boots Alliance

$54.40

-0.93 (-1.68%)

SNAP

Snap

$13.23

-0.77 (-5.50%)

BIIB

Biogen

$277.71

-4.25 (-1.51%)

NOW

ServiceNow

$218.44

-9.82 (-4.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 28

    Oct

  • 21

    Nov

  • 09

    Dec

  • 12

    Dec

14:09
10/23/19
10/23
14:09
10/23/19
14:09
General news
5-Yr Note Auction Coupon Rate data reported »

5-Yr Note Auction Coupon…

14:09
10/23/19
10/23
14:09
10/23/19
14:09
General news
5-Yr Note Auction Total Amount data reported »

5-Yr Note Auction Total…

SWM

Schweitzer-Mauduit

$39.78

1.11 (2.87%)

14:07
10/23/19
10/23
14:07
10/23/19
14:07
Initiation
Schweitzer-Mauduit initiated  »

Schweitzer-Mauduit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARVN

Arvinas

$19.41

3.01 (18.35%)

14:07
10/23/19
10/23
14:07
10/23/19
14:07
Hot Stocks
Arvinas spikes 17% after platform update including Protac trial data »

Earlier today, Arvinas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

WE

We Company

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

14:04
10/23/19
10/23
14:04
10/23/19
14:04
Periodicals
WeWork plans to cut up to 4,000 jobs in turnaround, FT reports »

WeWork (WE) plans to cut…

WE

We Company

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

CMCSA

Comcast

$45.65

-0.13 (-0.28%)

, CMCSK

Comcast

$0.00

(0.00%)

14:01
10/23/19
10/23
14:01
10/23/19
14:01
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CMCSA

Comcast

$45.65

-0.13 (-0.28%)

CMCSK

Comcast

$0.00

(0.00%)

DHR

Danaher

$137.96

0.76 (0.55%)

MMM

3M

$167.62

0.06 (0.04%)

NOC

Northrop Grumman

$349.80

-2.61 (-0.74%)

RTN

Raytheon

$202.20

-2.69 (-1.31%)

BAX

Baxter

$87.71

0.68 (0.78%)

DOW

Dow Inc.

$47.27

0.45 (0.96%)

HSY

Hershey

$149.87

0.14 (0.09%)

TWTR

Twitter

$38.30

-0.52 (-1.34%)

LUV

Southwest

$53.25

0.355 (0.67%)

TROW

T. Rowe Price

$109.40

1.4 (1.30%)

SWK

Stanley Black & Decker

$153.29

1.98 (1.31%)

HBAN

Huntington Bancshares

$14.48

0.045 (0.31%)

CTXS

Citrix

$103.72

-0.38 (-0.37%)

TSCO

Tractor Supply

$94.34

0.12 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 12

    Dec

HMC

Honda

$26.63

0.015 (0.06%)

14:00
10/23/19
10/23
14:00
10/23/19
14:00
Periodicals
Honda to sell only electric, hybrid cars in Europe starting in 2022, CNN says »

Honda said it intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EW

Edwards Lifesciences

$225.67

3.75 (1.69%)

, TSLA

Tesla

$255.10

-0.52 (-0.20%)

13:59
10/23/19
10/23
13:59
10/23/19
13:59
Earnings
Notable companies reporting after market close »

Notable companies…

EW

Edwards Lifesciences

$225.67

3.75 (1.69%)

TSLA

Tesla

$255.10

-0.52 (-0.20%)

PYPL

PayPal

$95.99

-1.41 (-1.45%)

MSFT

Microsoft

$136.25

-0.14 (-0.10%)

LVS

Las Vegas Sands

$59.16

0.58 (0.99%)

NOW

ServiceNow

$218.68

-9.58 (-4.20%)

F

Ford

$9.04

-0.025 (-0.28%)

LRCX

Lam Research

$233.15

-1.76 (-0.75%)

EBAY

eBay

$39.03

0.06 (0.15%)

ORLY

O'Reilly Automotive

$400.41

-0.16 (-0.04%)

XLNX

Xilinx

$95.26

-0.75 (-0.78%)

EFX

Equifax

$139.11

-0.15 (-0.11%)

ALGN

Align Technology

$217.63

4 (1.87%)

BMRN

BioMarin

$69.77

2.04 (3.01%)

FBHS

Fortune Brands

$58.73

0.22 (0.38%)

SLM

Sallie Mae

$9.10

0.04 (0.44%)

SAVE

Spirit Airlines

$37.74

0.49 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 13

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 07

    Dec

  • 09

    Dec

  • 12

    Dec

HPE

HP Enterprise

$15.93

-0.03 (-0.19%)

13:55
10/23/19
10/23
13:55
10/23/19
13:55
Conference/Events
HP Enterprise to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 09

    Dec

AXON

Axovant Sciences

$0.00

(0.00%)

13:53
10/23/19
10/23
13:53
10/23/19
13:53
Recommendations
Axovant Sciences analyst commentary  »

Axovant Sciences price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GGAL

Grupo Financiero

$12.75

0.4 (3.24%)

13:45
10/23/19
10/23
13:45
10/23/19
13:45
Options
Grupo Financiero call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.